Skip to main content


Fig. 1 | BMC Neurology

Fig. 1

From: Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

Fig. 1

Sample characteristics. A total number of ALS patients at the study site fullfilling the inclusion criteria were invited to participate in the survey. A subgroup responded and participated in the study. Data were collected online or via telephone survey. Data sets for severity of spasticity (Numeric Rating Scale, NRS), recommendation of treatment (Net Promoter Score, NPS) and treatment satisfaction (Treatment Satisfaction Questionnaire for Medication, TSQM-9) were obtained. n = number of patients and analysable datasets, respectively

Back to article page